Brought to you by 
Immunomedics grants UCB rights to epratuzumab; rights returned
22 Apr 2021
Executive Summary
Immunomedics (MAbs for cancer and autoimmune diseases) has granted UCB exclusive worldwide rights to develop, market, and sell the humanized monoclonal antibody epratuzumab for all autoimmune disease indications. The compound targets an antigen called CD22 and has already shown potential for systemic lupus erythematosus (SLE) and Sjögren's syndrome.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Immunomedics grants UCB rights to epratuzumab; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice